Table 3.
Clinical and biological characteristics of respiratory virus infection episodes in allo-HSCT recipients according to timing of CARV
| CARV before d + 180 (n = 227) | CARV after d + 180 (n = 149) | P value | |
|---|---|---|---|
| Transplant characteristics | |||
| ATG as part of conditioning | 56 (25) | 34 (23) | 0.4 |
| GVHD prophylaxis | 0.06 | ||
| Sir-Tac | 15 (7) | 22 (15) | |
| CsA + MTX | 32 (14) | 24 (16) | |
| Post-Cy | 121 (53) | 71 (48) | |
| CsA + PDN and others | 59 (26) | 32 (22) | |
| HLA mismatch, n (%) | 116 (51) | 65 (44) | 0.09 |
| Type of donor, n (%) | 0.3 | ||
| HLA-identical sibling donor | 64 (28) | 51 (34) | |
| Unrelated donor | 50 (22) | 40 (27) | |
| Umbilical cord blood | 50 (22) | 26 (17) | |
| Haplo-identical family donor | 63 (28) | 32 (21) | |
| Immunodeficiency scoring index, n (%)a | |||
| ANC < 0.5 × 109/L (3 pts) | 46 (20) | 5 (3) | 0.001 |
| ALC < 0.2 × 109/L (3 pts) | 68 (30) | 12 (8) | 0.001 |
| Age ≥ 40 year (2 pts) | 150 (66) | 101 (68) | 0.4 |
| Myeloablative conditioning regimen (1 pt) | 133 (59) | 76 (51) | 0.09 |
| GvHD (acute or chronic; 1 pt) | 82 (36) | 87 (58) | 0.001 |
| Corticosteroids (1 pt) | 86 (38) | 51 (34) | 0.3 |
| Recent or preengraftment allo-HSCT (1 pt) | 64 (28) | 0 | 0.001 |
| ISI, n (%) | 0.001 | ||
| Low risk (0–2) | 78 (34) | 57 (38) | |
| Moderate risk (3–6) | 96 (42) | 83 (56) | |
| High risk (7–12) | 53 (23) | 9 (6) | |
| Other characteristicsa | |||
| On IS, n (%) | 208 (92) | 104 (70) | 0.001 |
| ALC < 0.1 × 109/L, n (%) | 51 (22) | 4 (3) | 0.001 |
| ALC < 0.5 × 109/L, n (%) | 119 (52) | 25 (17) | 0.001 |
| RVI characteristics and clinical consequences | |||
| CARV LRTD, n (%) | 87 (38) | 53 (36) | 0.3 |
| Possible | 40 (46) | 32 (60) | |
| Proven | 47 (54) | 21 (40) | |
| Hospital admission, n (%) | 115 (51) | 40 (27) | 0.001 |
| Fever during CARV, n (%) | 148 (65) | 82 (55) | 0.03 |
| Day +90 overall mortality rate, n (%) | 25 (11) | 5 (3) | 0.005 |
CARV community-acquired respiratory virus, IFD invasive pulmonary infectious fungal disease, ATG antithymocyte globuline, GvHD graft-versus-host disease, Sir sirolimus, Tac tacrolimus, CsA cyclosporine A, MTX methotrexate, Post-Cy post-transplant cyclophosphamide, PDN prednisone, Allo-HSCT allogeneic hematopoietic stem cell transplantation, ANC absolute neutrophil count, ALC absolute lymphocyte count, IS immunosuppressants, LRTD lower respiratory tract disease
aAll variables were captured at the time of CARV diagnosis